CONTEXT: Little is known about the role of testosterone and estradiol on cognition in healthy older men. OBJECTIVE: The cognitive effects of increasing or lowering testosterone or estradiol were examined. DESIGN:Cognition was assessed before and after 6 wk of double-blind placebo-controlled hormone modification. SETTING: The study was conducted at an academic medical center. PARTICIPANTS: Healthy older (ages 60-80 yr) and younger men (ages 25-35 yr) were recruited from the community. INTERVENTION: Men were randomized to one of four treatments: 1) maintain testosterone and estradiol at eugonadal levels for young men (GnRH agonist + testosterone gel); 2) block testosterone's conversion to estradiol (GnRH agonist + testosterone gel + aromatase inhibitor); 3) induce hypogonadism (GnRH agonist alone); and 4) all placebo. MAIN OUTCOME MEASURES: Measures of executive function, memory, and spatial cognition were obtained before and after treatment. Hormone levels were obtained 10 times over the course of the study. RESULTS: Counter to expectations, hormone treatment did not affect cognition (P > 0.10). Free testosterone was positively related to spatial cognition in older men after treatment and controlling for age and estradiol level or exclusion of the hypogonadal men (P = 0.02). Estradiol was negatively associated with working memory controlling for the same variables (P = 0.01). Blinding to treatment assignment was maintained, with the exception of the hypogonadal group. CONCLUSIONS: A significant change in sex hormone status, including complete hypogonadism, does not modify cognition in men. These findings, along with studies that show a risk for neurodegenerative disease in those with low testosterone, suggest that sex hormone status may be important for neuroprotection in aging but not modulation of normal day-to-day cognitive function.
RCT Entities:
CONTEXT: Little is known about the role of testosterone and estradiol on cognition in healthy older men. OBJECTIVE: The cognitive effects of increasing or lowering testosterone or estradiol were examined. DESIGN: Cognition was assessed before and after 6 wk of double-blind placebo-controlled hormone modification. SETTING: The study was conducted at an academic medical center. PARTICIPANTS: Healthy older (ages 60-80 yr) and younger men (ages 25-35 yr) were recruited from the community. INTERVENTION: Men were randomized to one of four treatments: 1) maintain testosterone and estradiol at eugonadal levels for young men (GnRH agonist + testosterone gel); 2) block testosterone's conversion to estradiol (GnRH agonist + testosterone gel + aromatase inhibitor); 3) induce hypogonadism (GnRH agonist alone); and 4) all placebo. MAIN OUTCOME MEASURES: Measures of executive function, memory, and spatial cognition were obtained before and after treatment. Hormone levels were obtained 10 times over the course of the study. RESULTS: Counter to expectations, hormone treatment did not affect cognition (P > 0.10). Free testosterone was positively related to spatial cognition in older men after treatment and controlling for age and estradiol level or exclusion of the hypogonadal men (P = 0.02). Estradiol was negatively associated with working memory controlling for the same variables (P = 0.01). Blinding to treatment assignment was maintained, with the exception of the hypogonadal group. CONCLUSIONS: A significant change in sex hormone status, including complete hypogonadism, does not modify cognition in men. These findings, along with studies that show a risk for neurodegenerative disease in those with low testosterone, suggest that sex hormone status may be important for neuroprotection in aging but not modulation of normal day-to-day cognitive function.
Authors: M M Cherrier; A M Matsumoto; J K Amory; M Johnson; S Craft; E R Peskind; M A Raskind Journal: Psychoneuroendocrinology Date: 2006-12-04 Impact factor: 4.905
Authors: M M Cherrier; S Asthana; S Plymate; L Baker; A M Matsumoto; E Peskind; M A Raskind; K Brodkin; W Bremner; A Petrova; S LaTendresse; S Craft Journal: Neurology Date: 2001-07-10 Impact factor: 9.910
Authors: Jessica A Siegel; Laura A Young; Michelle B Neiss; Mary H Samuels; Charles E Roselli; Jeri S Janowsky Journal: Behav Neurosci Date: 2008-10 Impact factor: 1.912
Authors: Marielle H Emmelot-Vonk; Harald J J Verhaar; Hamid R Nakhai Pour; André Aleman; Tycho M T W Lock; J L H Ruud Bosch; Diederick E Grobbee; Yvonne T van der Schouw Journal: JAMA Date: 2008-01-02 Impact factor: 56.272
Authors: Gioia M Guerrieri; Paul G Wakim; P A Keenan; Linda A Schenkel; Kate Berlin; Carolyn J Gibson; David R Rubinow; Peter J Schmidt Journal: Neuropsychologia Date: 2015-12-21 Impact factor: 3.139
Authors: Ari L Mendell; Sarah Atwi; Craig D C Bailey; Dan McCloskey; Helen E Scharfman; Neil J MacLusky Journal: Brain Struct Funct Date: 2016-06-09 Impact factor: 3.270
Authors: Mihail F Zilbermint; Amy B Wisniewski; Xiaoqiang Xu; Ola A Selnes; Adrian S Dobs Journal: Drug Alcohol Depend Date: 2012-09-26 Impact factor: 4.492